<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1276">
  <stage>Registered</stage>
  <submitdate>30/08/2006</submitdate>
  <approvaldate>30/08/2006</approvaldate>
  <nctid>NCT00370864</nctid>
  <trial_identification>
    <studytitle>Study of a Pandemic Influenza Vaccine in Children</studytitle>
    <scientifictitle>Phase II Study of a Pandemic Influenza Vaccine in Children</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CSLCT-PAN-05-17</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Influenza</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - H5N1 pandemic influenza vaccine

Other interventions: H5N1 pandemic influenza vaccine


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and immunogenicity</outcome>
      <timepoint />
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy children aged greater or equal to 6 months to less than 9 years

          -  Normal gestation period</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>8</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  History of clinically significant medical conditions

          -  History of Guillain Barre syndrome or active neurological disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>220</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC,WA</recruitmentstate>
    <hospital>Murdoch Childrens Research Institute - Melbourne</hospital>
    <hospital>Princess Margaret Hospital for Children - Perth</hospital>
    <postcode>3052 - Melbourne</postcode>
    <postcode> - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Seqirus</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The World Health Organisation has warned that an influenza pandemic is inevitable. The avian
      influenza strain H5N1 is one of the leading candidates to cause the next influenza pandemic.
      Children are likely to be a special target group for vaccination; therefore, this study will
      test the safety and immunogenicity of an H5N1 pandemic influenza vaccine in healthy children.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00370864</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Terry M Nolan, Prof</name>
      <address>Murdoch Childrens Research Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>